Psoriatic Arthritis News

Patients with inflammatory rheumatic disease exhibited a higher incidence of COVID-19 hospitalization than the general population, and those with rheumatoid arthritis are at a greater risk for severe outcomes, according to data.

Glucocorticoids, even at a low dose, may increase the risk for COVID-19, while immunomodulatory treatments appear safe for patients with inflammatory arthritis, according to data published in Arthritis Research & Therapy.

Patients with systemic autoimmune rheumatic diseases and COVID-19 may be at greater risk for hospitalization, ICU admission, acute renal failure and venous thromboembolism, according to data published in Arthritis & Rheumatology.

Secukinumab in doses of 300 and 150 mg significantly improves signs and symptoms of axial disease, compared with placebo, in patients with psoriatic arthritis with axial manifestations, according to data.

Patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and lupus often avoided office visits and lab testing in the early months of the COVID-19 pandemic, according to data published in The Journal of Rheumatology.

The doctor-patient relationship is evolving from a paternalistic to a collaborative model of care across the rheumatology specialty.

Drug maker Gilead Sciences has announced it will no longer pursue FDA approval for its janus kinase inhibitor filgotinib in the treatment of rheumatoid arthritis, according to a company press release.

Upadacitinib, in doses of either 15 or 30 mg, is superior to placebo in improving signs and symptoms of active psoriatic arthritis among patients who are intolerant, or had an inadequate response, to a biologic DMARD, according to data.

Among patients with stable psoriatic arthritis receiving tofacitinib with methotrexate, some may be able to discontinue methotrexate without changes in disease activity or safety, according to data published in The Lancet Rheumatology.

Systemic lupus erythematosus is 2.3 times more prevalent among patients with psoriatic arthritis compared with the general population, according to data published in The Journal of Rheumatology.